ACADIA Pharmaceuticals Help Lift Biotech ETFs
While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength…
SBIO
ALPS Medical Breakthroughs ETF
$41.39 +$0.79
(+1.95%)
As of 1:00:00 AM EDT | 12/06/19 | Market Closed
SBIO Trading Data
Open
$40.86
Low Price
$40.82
High Price
$41.41
Previous Last Price
$40.6
Bid Size
$0 X 0
Ask Size
$0 X 0
SBIO Portfolio Data
AUM
$204,650,000
Shares
5,000
PE Ratio
0
Price / Book Ratio
3.52
Expense Ratio
0.5
Net Asset Value
$40.93
Volume
Volume
48,000
Avg. Volume (YDT)
36,723
Dollar Volume
$0
Weekly Avg. Volume
44,400
Monthly Avg. Volume
37,205
Quarterly Avg. Volume
32,903
SBIO Fund Description
The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
SBIO Chart
SBIO Summary
Fund Family
ALPS Holdings
Tracks This Index
ALPS Medical Breakthroughs ETF
Inception Date
2015-01-05
Asset Class
Portfolio-Multi Asset
Asset Class Size
Healthcare
SBIO Classification
Region (General)
Global
Region (Specific)
Sector
Health Care
Equity Index
Leveraged Family
SBIO Holdings
Top 10 Holdings
ACADIA Pharmaceuticals Inc. (ACAD)
5.26%
Allakos Inc. (ALLK)
4.44%
United Therapeutics Corp. (UTHR)
4.3%
MorphoSys AG (MOR)
3.86%
Immunomedics Inc. (IMMU)
3.76%
Mirati Therapeutics Inc. (MRTX)
3.61%
Global Blood Therapeutics Inc. (GBT)
3.55%
FibroGen Inc. (FGEN)
3.52%
Alkermes PLC (ALKS)
3.48%
Halozyme Therapeutics Inc. (HALO)
2.95%
Total SBIO Holdings
Total Holdings: 79
ACADIA Pharmaceuticals Inc. (ACAD)
5.26%
Allakos Inc. (ALLK)
4.44%
United Therapeutics Corp. (UTHR)
4.3%
MorphoSys AG (MOR)
3.86%
Immunomedics Inc. (IMMU)
3.76%
Mirati Therapeutics Inc. (MRTX)
3.61%
Global Blood Therapeutics Inc. (GBT)
3.55%
FibroGen Inc. (FGEN)
3.52%
Alkermes PLC (ALKS)
3.48%
Halozyme Therapeutics Inc. (HALO)
2.95%
Emergent BioSolutions Inc. (EBS)
2.78%
PTC Therapeutics Inc. (PTCT)
2.71%
Acceleron Pharma Inc. (XLRN)
2.47%
Arena Pharmaceuticals Inc. (ARNA)
2.45%
Deciphera Pharmaceuticals Inc. (DCPH)
2.44%
uniQure NV (QURE)
2.34%
Ra Pharmaceuticals Inc. (RARX)
2.32%
Agios Pharmaceuticals Inc. (AGIO)
2.31%
Ligand Pharmaceuticals Inc. (LGND)
2.21%
Eidos Therapeutics Inc. (EIDX)
2.14%
Akcea Therapeutics Inc. (AKCA)
1.84%
Apellis Pharmaceuticals Inc. (APLS)
1.8%
Gossamer Bio Inc. (GOSS)
1.73%
Madrigal Pharmaceuticals Inc. (MDGL)
1.69%
Dicerna Pharmaceuticals Inc. (DRNA)
1.62%
Epizyme Inc. (EPZM)
1.57%
Enanta Pharmaceuticals Inc. (ENTA)
1.26%
Cara Therapeutics Inc. (CARA)
1.18%
Constellation Pharmaceuticals Inc. (CNST)
1.08%
Orchard Therapeutics PLC (ORTX)
1.04%
ArQule Inc. (ARQL)
1.04%
Y-mAbs Therapeutics Inc. (YMAB)
1.03%
Krystal Biotech Inc. (KRYS)
0.99%
Fate Therapeutics Inc. (FATE)
0.99%
G1 Therapeutics Inc. (GTHX)
0.93%
Achillion Pharmaceuticals Inc. (ACHN)
0.91%
Vericel Corp. (VCEL)
0.86%
Anika Therapeutics Inc. (ANIK)
0.84%
Rhythm Pharmaceuticals Inc. (RYTM)
0.8%
Principia Biopharma Inc. (PRNB)
0.78%
Kura Oncology Inc. (KURA)
0.72%
MeiraGTx Holdings PLC (BFYQFJ)
0.69%
UroGen Pharma Ltd. (URGN)
0.65%
Agenus Inc. (AGEN)
0.58%
Magenta Therapeutics Inc. (MGTA)
0.57%
AC Immune SA (ACIU)
0.57%
Voyager Therapeutics Inc. (VYGR)
0.55%
Viking Therapeutics Inc. (VKTX)
0.55%
ImmunoGen Inc. (IMGN)
0.53%
ChemoCenyx Inc. (CCXI)
0.49%
Progenics Pharmaceuticals Inc. (PGNX)
0.47%
Crinetics Pharmaceuticals Inc. (CRNX)
0.47%
MacroGenics Inc. (MGNX)
0.45%
Rigel Pharmaceuticals Inc. (RIGL)
0.41%
Assembly Biosciences Inc. (ASMB)
0.38%
AMAG Pharmaceuticals Inc. (AMAG)
0.38%
Puma Biotechnology Inc. (PBYI)
0.37%
PDL BioPharma Inc. (PDLI)
0.36%
ProQR Therapeutics NV (PRQR)
0.34%
MediciNova Inc. (MNOV)
0.34%
AnaptysBio Inc. (ANAB)
0.34%
Scholar Rock Holding Corp. (SRRK)
0.33%
Corbus Pharmaceuticals Holdings Inc. (CRBP)
0.31%
Xenon Pharmaceuticals Inc. (XENE)
0.25%
Minerva Neurosciences Inc. (NERV)
0.25%
Albireo Pharma Inc. (ALBO)
0.25%
MannKind Corp. (MNKD)
0.23%
GlycoMimetics Inc. (GLYC)
0.22%
Athersys Inc. (ATHX)
0.22%
Kiniksa Pharmaceuticals Ltd. (KNSA)
0.19%
Concert Pharmaceuticals Inc. (CNCE)
0.17%
Marker Therapeutics Inc. (MRKR)
0.14%
PhaseBio Pharmaceuticals Inc. (PHAS)
0.1%
Acorda Therapeutics Inc. (ACOR)
0.1%
Aduro Biotech Inc. (ADRO)
0.09%
Savara Inc. (SVRA)
0.04%
Cash Equivalent
0.02%
ALPS Medical Breakthroughs ETF (SBIO)
0%
Corium International Inc. (CORI-CVR)
0%
SBIO Technicals
Alpha
-2.04
Beta
1.59
Leverage
Long
Standard Deviation
2.04
SBIO Dividends
Dividend Date
2018-12-20
Latest Dividend
0.784
Annual Dividend
0.78
Annual Dividend Rate
0.78
Annual Dividend Yield
1.92
SBIO Performance
YTD Return
47.09%
1 Year Return
26.85%
3 Year Return
74.49%
5 Year Return
0%
10 Year Return
66.63%
SBIO Related Articles
Biotech ETFs Jump: Keep an Eye on XBI, IBB & SBIO
Biotech ETFs are movin’ on up on news that Pfizer is buying Array BioPharma for over $10 billion. SPDR S&P Biotech…
Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal
Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY)…
3 Biotech Sector ETFs Bucked the Risk-Off Trend
While the rest of the markets retreated on a round of risk-off selling in response to President Donald Trump’s threats…
A Targeted ETF to Capture M&A, Consolidation in the Biotech Space
The biotechnology space is filled with new drug makers and treatments that help make lives better, and large pharma has…
Healthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain Outlook
Healthcare companies were among the worst performing stocks Wednesday, with biotechnology sector-specific ETFs taking the brunt of the hit, after…
© 2019 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.